Literature DB >> 2447572

Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.

M Rademaker1, R H Thomas, G Provost, J A Beacham, E D Cooke, J D Kirby.   

Abstract

Thirteen patients with Raynaud's phenomenon secondary to systemic sclerosis received three 8-hour infusions of a synthetic prostacyclin analogue (Iloprost) on consecutive days and were followed-up over a period of 10 weeks during the winter of 1985/86. Six weeks after infusion, digital peripheral vascular resistance had fallen (P less than 0.05) and dicrotic notch proportion of pulse amplitude increased (P less than 0.05). Digital blood flow and pulse amplitude (measured by photoplethymography) were also increased but did not reach statistical significance. The trend of improvement in these blood flow parameters was still evident after 10 weeks. The number of cutaneous lesions (digital ulcers, etc) fell from 26 lesions before infusion to only 7 lesions by the end of the study, confirming the subjective improvement reported by the patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447572      PMCID: PMC2428395          DOI: 10.1136/pgmj.63.742.617

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells.

Authors:  R J Gryglewski; S Moncada; R M Palmer
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

2.  Treatment of childhood Raynaud's disease by transdermal prostaglandin E2 analogue.

Authors:  D B Dunger; M J Dillon; C Daman-Willems; E D Cooke; S A Bowcock
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

3.  Photoplethysmography of the distal pulp in the assessment of the vasospastic hand.

Authors:  E D Cooke; S A Bowcock; A T Smith
Journal:  Angiology       Date:  1985-01       Impact factor: 3.619

4.  Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man.

Authors:  A J Cowley; S Heptinstall; J R Hampton
Journal:  Thromb Haemost       Date:  1985-02-18       Impact factor: 5.249

5.  Prostaglandin E1 vasospastic disease and thermography.

Authors:  V Kyle; G Parr; R Salisbury; P P Thomas; B Hazleman
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

6.  CL115,347, an analogue of prostaglandin E2. Peripheral circulatory effects of single ascending doses administered transdermally in normal subjects and in patients with Raynaud's phenomenon.

Authors:  E D Cooke; S A Bowcock; C J Watkins; M H Rustin; J D Kirby
Journal:  Angiology       Date:  1985-12       Impact factor: 3.619

7.  Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases.

Authors:  O Meyer; T Haïm; A Dryll; J Lansaman; A Ryckewaert
Journal:  Clin Exp Rheumatol       Date:  1983 Jan-Mar       Impact factor: 4.473

8.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

9.  Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).

Authors:  P M Dowd; M F Martin; E D Cooke; S A Bowcock; R Jones; P A Dieppe; J D Kirby
Journal:  Br J Dermatol       Date:  1982-01       Impact factor: 9.302

10.  Endothelial injury in scleroderma.

Authors:  M B Kahaleh; G K Sherer; E C LeRoy
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Raynaud's syndrome.

Authors:  E D Cooke; A N Nicolaides
Journal:  BMJ       Date:  1990-03-03

2.  A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.

Authors:  H I Torley; R Madhok; H A Capell; R M Brouwer; P J Maddison; C M Black; H Englert; J A Dormandy; H R Watson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 3.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

4.  A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.

Authors:  D Biasi; P Caramaschi; A Carletto; S Zeminian; F Schiavon; L M Bambara
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

5.  Multiple microemboli after disintegration of clot during thrombolysis for acute myocardial infarction.

Authors:  P J Stafford; C J Strachan; R Vincent; D A Chamberlain
Journal:  BMJ       Date:  1989-11-25

6.  Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

Authors:  M Rademaker; E D Cooke; N E Almond; J A Beacham; R E Smith; T G Mant; J D Kirby
Journal:  BMJ       Date:  1989-03-04

7.  The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery.

Authors:  Gaetano de Donato; Gualberto Gussoni; Gianmarco de Donato; Giuseppe Maria Andreozzi; Erminio Bonizzoni; Antonino Mazzone; Attilio Odero; Giovanni Paroni; Carlo Setacci; Piergiorgio Settembrini; Fabrizio Veglia; Romeo Martini; Francesco Setacci; Domenico Palombo
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

Review 8.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 9.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

10.  Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.

Authors:  Paola Caramaschi; Domenico Biasi; Marcello Ferrari; Alessandro Volpe; Nicola Martinelli; Antonio Carletto; Paola Dal Forno; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2004-02-13       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.